EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED

Company Type: Primarily a pharmaceutical manufacturer, also engaged in sales, marketing, and distribution.

Company Introduction:

EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED is the Indian subsidiary of Eisai Co., Ltd., a leading global research-based pharmaceutical company headquartered in Japan. The company operates in India with a strong commitment to its "human health care (hhc)" mission, focusing on delivering innovative pharmaceutical products to meet unmet medical needs. Their operations encompass both the manufacturing of active pharmaceutical ingredients (APIs) and formulations, as well as the commercial activities of marketing, sales, and distribution of their portfolio of drugs across India. They play a crucial role in bringing Eisai's global therapeutic advancements, particularly in neurology, oncology, and other specialist areas, to the Indian market.

EISAI PHARMACEUTICALS INDIA PRIVATE LIMITED manufactures and/or markets the following:

* Aricept (Donepezil)

* Lenvima (Lenvatinib)

* Fycompa (Perampanel)

* Poxel (Imeglimin) - likely for clinical trials or future launch, as it's partnered with Poxel SA.

* Various generic medicines

Please note that product availability may vary, and this list may not be exhaustive. It's always best to consult the company's official website or local healthcare professionals for the most up-to-date and accurate information.